Skip to main content
SpringerLink
Log in

Immuntherapeutika und Zytostatika

  • Chapter
Arzneiverordnungs-Report 2004

  • 67 Accesses

Zusammenfassung

Hauptgruppen der Immuntherapeutika sind Zytokine (Interferone, koloniestimulierende Faktoren) und Immunsuppressiva. Betainterferone werden in weiter steigendem Umfang zur Behandlung der multiplen Sklerose eingesetzt, Alfainterferone vor allem bei der Hepatitis C. Schwerpunkt der Immunsuppressiva ist die Prophylaxe von Abstoßungsreaktionen bei trans-plantierten Patienten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American Cancer Society (2002): Complementary and Alternative Cancer Methods Handbook. American Cancer Society.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (1996): Wie verträglich sind Echinacea-haltige Präparate? Dtsch Ärztebl 93: A–2723.

    Google Scholar 

  • Beverly P (1995): Tumorimmunologie. In: Roitl JM, Broxtoff J, Male DK (Hrsg.): Kurzes Lehrbuch der Immunologie. 3. Aufl. Thieme, Stuttgart New York, S. 246–257.

    Google Scholar 

  • Brinkeborn RM, Shah DV, Degenring FH (1999): Echinaforce® and other Echinacea fresh plant preparations in the treatment of the common cold. Phytomedicine 6: 1–5.

    Article  PubMed  CAS  Google Scholar 

  • Collet JP, Shapiro S, Ernst P, Renzi P, Ducruet T, Robinson A, PARI-IS Study Steering Committee and Research Group (1997): Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 156:1719–1724.

    CAS  Google Scholar 

  • Dold U, Edler L, Mäurer HC et al. (1991): Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. Thieme, Stuttgart.

    Google Scholar 

  • Dorsch W (1996): Klinische Anwendung von Extrakten aus Echinacea purpurea oder Echinacea pallida. Klinische Wertung kontrollierter klinischer Studien. Z Ärztl Fortbild (Jena) 90:117–122.

    CAS  Google Scholar 

  • Dunn CJ, Goa KL (2000): Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 59: 681–717.

    Article  PubMed  CAS  Google Scholar 

  • Ernst E (2001a): A primer of complementary and alternative medicine commonly used by cancer patients. Med J Aust 174: 88–92.

    PubMed  CAS  Google Scholar 

  • Ernst E (2001b): Mistletoe for cancer? Eur J Cancer 37: 9–11.

    Article  PubMed  CAS  Google Scholar 

  • Ernst E (2001c): The desktop guide to complementary and alternative medicine an evidence-based approach. Mosby, Hartcourt.

    Google Scholar 

  • Fischer T (2002): Der Signalhemmer Imatinib Mesilat (STI571). Wirkprinzip und klinische Anwendung. UNI-MED, Bremen.

    Google Scholar 

  • Grimm W, Müller H-H (1999): A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. Am J Med 106:138–143.

    Article  PubMed  CAS  Google Scholar 

  • Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ (1990): Increased secretion of tumor necrosis factor-alpha, interleukin-1, and interleukin-6 by human mono-nuclear cells exposed to β-galactoside-specific lectin from clinically applied mistletoe extracts. Cancer Res 50:3322–3326.

    PubMed  CAS  Google Scholar 

  • Heiny BM, Albrecht V, Beuth J (1998): Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galac-tose-specific lectin standardized mistletoe extract. Anticancer Res 18: 583–586.

    PubMed  CAS  Google Scholar 

  • Hohenberger P, Reichardt P, Stroszczynski C, Schneider U, Hossfeld DK (2003): Gastrointestinale Stromatumoren — Tumorentität und Therapie mit Imatinib. Dtsch Ärztebl 100: A1612–A1618.

    Google Scholar 

  • Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. (1996): Intramuscular interferon β-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Colloborative Research Group (MSCRG). Ann Neurol 39:285–294.

    Article  PubMed  CAS  Google Scholar 

  • Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K et al. for the Consensus Interferon Study Group (1999): Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Am J Gastroenterol 94: 3583–3588.

    Article  PubMed  CAS  Google Scholar 

  • Kao JH, Chen PJ, Lai MY, Chen DS (2000): Efficacy of consensus interferon in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 15:1418–1423.

    Article  PubMed  CAS  Google Scholar 

  • Kienle GS, Kiene H (2004): Klinische Studien zur Misteltherapie onkologischer Erkrankungen. Dtsch Zeitschr Onkol 36:17–24.

    Google Scholar 

  • Kienle GS, Kiene H (2003): Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen. Schattauer, Stuttgart.

    Google Scholar 

  • Kleijnen J, Knipschild P (1994): Mistletoe treatment for cancer. Review of controlled trials in humans. Phytomedicine 1: 255–260.

    Article  PubMed  CAS  Google Scholar 

  • Lenartz D, Dott U, Menzel J, Schierholz JM, Beuth J (2000): Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20: 2073–2076.

    PubMed  CAS  Google Scholar 

  • McHutchinson JG, Gordon SC, Schiff ER (1998): Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485–1492.

    Article  Google Scholar 

  • Melchart D, Walther E, Linde K, Brandmaier R, Lersch C (1998): Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial. Arch Fam Med 7: 541–545.

    Article  PubMed  CAS  Google Scholar 

  • Mullins RJ (1998): Echinacea-associated anaphylaxis. Med J Aust 16:170–171.

    Google Scholar 

  • Peggs K, Mackinnon S (2003): Imatinib Mesylate — The new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348:1048–1050.

    Article  PubMed  Google Scholar 

  • Pforte A, Emmerich B (1993): Störungen der Infektabwehr bei Patienten mit chronischer Bronchitis: präventive und supportive Möglichkeiten. Pneumologie 47: 395–402.

    PubMed  CAS  Google Scholar 

  • Roitt IM, Brostoff J, Male DK (1991): Kurzes Lehrbuch der Immunologie. 2. Aufl., Thieme, Stuttgart, New York.

    Google Scholar 

  • Rote Liste 2004. Editio Cantor Verlag, Aulendorf.

    Google Scholar 

  • Scheer R, Bauer R, Becker H, Berg PA, Fintelmann V (2001): Vorwort S.V. In: Scheer R. et al. (Hrsg.): Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik, KVC, Essen.

    Google Scholar 

  • Stein G, Henn W, von Laue H, Berg P (1998): Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy. Eur J Med Res 3: 194–202.

    PubMed  CAS  Google Scholar 

  • Steuer-Vogt MK, Bonkowsky V, Ambrosch P, Scholz M, Neiß A, Strutz J, Hennig M, Lenarz T, Arnold W (2001): The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 37:23–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Deutsches Krebsforschungszentrum, Abt. Perinatale Toxikologie, Im Neuenheimer Feld 280, 69120, Heidelberg

    Prof. Dr. med. W. Jens Zeller

Authors
  1. Prof. Dr. med. W. Jens Zeller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Jens Zeller, W. (2004). Immuntherapeutika und Zytostatika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2004. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18513-7_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18513-7_32

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21359-8

  • Online ISBN: 978-3-642-18513-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation